Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases?

References

• Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004; 11: 207–24
   PubMed Web of Science ®Google Scholar
• Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165–76
   PubMed Web of Science ®Google Scholar
• Clezardin P. Anti-tumour activity of zoledronic acid. Cancer Treat Rev 2005; 31(Suppl 3)1–8
   PubMed Web of Science ®Google Scholar
• Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 2003; 88: 1631–40
   PubMed Web of Science ®Google Scholar
• Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaum C, Faye JC, et al. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 2006; 6: 60
   PubMed Web of Science ®Google Scholar
• Rogers, MJ, Gordon, S, Benford, HL, Coxon, FP, Luckman, SP, Monkkonen, J,, et al Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88(12 Suppl):2961–78.
   PubMedGoogle Scholar
• Walker K, Olson MF. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr Opin Genet Dev 2005; 15: 62–8
   PubMed Web of Science ®Google Scholar
• Cameron D, Fallon M, Diel I. Ibandronate: Its role in metastatic breast cancer. Oncologist 2006; 11(Suppl 1)27–33
   PubMed Web of Science ®Google Scholar
• Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol 2008; 19: 420–32
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879–82
   PubMed Web of Science ®Google Scholar
• Smith MR. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev 2005; 31(Suppl 3)19–25
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–68
   PubMed Web of Science ®Google Scholar
• Saad F, Chen YM, Gleason DM, Chin J. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 2007; 5: 390–6
   PubMed Web of Science ®Google Scholar
• Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007; 5: 271–7
   PubMed Web of Science ®Google Scholar
• Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008–12
   PubMed Web of Science ®Google Scholar
• Johnson, K, Gable, P, Kaime, E, Luiken, G, Castillos, T, Hu, J. Significant deterioration in renal function with the new bisphosphonate, zoledronic acid. Proc Am Soc Clin Oncol 2003;22, Abstract 2968.
   PubMed Web of Science ®Google Scholar
• McDermott RS, Kloth DD, Wang H, Hudes GR, Langer CJ. Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model. J Support Oncol 2006; 4: 524–9
   PubMedGoogle Scholar
• Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64: 281–9
   PubMed Web of Science ®Google Scholar
• Balla, J. The issue of renal safety of zoledronic acid from a nephrologist's point of view. Oncologist 2005;10:306–8, Author reply 11–2.
   PubMed Web of Science ®Google Scholar
• Diel IJ, Bergner R, Grotz KA. Adverse effects of bisphosphonates: Current issues. J Support Oncol 2007; 5: 475–82
   PubMedGoogle Scholar
• Chang, JT, Green, L, Beitz, J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676–9, Discussion –9.
   PubMed Web of Science ®Google Scholar
• Mazj, S, Litchtman, S. Renal dysfunction associated with bisphosphonate use: Retrospective analysis of 293 patients with respect to age and other clinical characteristics. J Clin Oncol 2004;22(22 Suppl 735) Abstract 8039.
   Google Scholar
• Barot, K, Wu, S, Zhu, X. Risk of renal dysfunction with zoledronic acid in patients with metastatic solid tumours. J Clin Oncol 2008;26(15 Suppl) Abstract 20530.
   Google Scholar
• Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol 2007; 14: 1071–5
   PubMed Web of Science ®Google Scholar
• Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001; 61: 4418–24
   PubMed Web of Science ®Google Scholar
• Verdijk R, Franke HR, Wolbers F, Vermes I. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett 2007; 246: 308–12
   PubMed Web of Science ®Google Scholar
• Journe F, Chaboteaux C, Magne N, Duvillier H, Laurent G, Body JJ. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. Breast Cancer Res 2006; 8: R2
   PubMed Web of Science ®Google Scholar
• Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000; 15: 2211–21
   PubMed Web of Science ®Google Scholar
• Journe F, Magne N, Chaboteaux C, Kinnaert E, Bauss F, Body JJ. Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines. Clin Exp Metastasis 2006; 23: 135–47
   PubMed Web of Science ®Google Scholar
• Neudert M, Fischer C, Krempien B, Bauss F, Seibel MJ. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: Model characterisation and in vivo effects of ibandronate on tumour growth. Int J Cancer 2003; 107: 468–77
   PubMed Web of Science ®Google Scholar
• Neudert M, Fischer C, Krempien B, Seibel MJ, Bauss F. A rapid histological score for the semiquantitative assessment of bone metastases in experimental models of breast cancer. Onkologie 2008; 31: 521–7
   PubMedGoogle Scholar
• Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399–405
   PubMed Web of Science ®Google Scholar
• Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133–7
   PubMed Web of Science ®Google Scholar
• Dumon, JC, Journe, F, Kheddoumi, N, Lagneaux, L, Body, JJ. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 2004;45:521–8, Discussion 8–9.
   PubMed Web of Science ®Google Scholar
• Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57: 3890–4
   PubMed Web of Science ®Google Scholar
• Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62: 6538–44
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002; 5: 231–5
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Ohlmann C, Olbert P, Hegele A. High dose ibandronate is effective and well tolerated in the treatment of pain and hypercalacaemia due to metastatic urological cancer. Eur J Cancer 2003; 1(Suppl 5)S270
   Google Scholar
• Coleman RE, Purohit OP, Black C, Vinholes JJ, Schlosser K, Huss H, et al. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1999; 10: 311–6
   PubMed Web of Science ®Google Scholar
• Martin T, Grill V. Bisphosphonates – mechanisms of action. Aust Prescrib 2000; 23: 130–2
   Google Scholar
• Leyland-Jones B. Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease. Eur J Cancer Suppl 2004; 2: 9–12
   Web of Science ®Google Scholar
• Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: A clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004; 44: 951–65
   PubMed Web of Science ®Google Scholar
• Cameron, D. Patient management issues in metastatic bone disease. Semin Oncol 2004;31(5 Suppl 10):79–82.
   PubMed Web of Science ®Google Scholar
• Body JJ. Bisphosphonates for malignancy-related bone disease: Current status, future developments. Support Care Cancer 2006; 14: 408–18
   PubMed Web of Science ®Google Scholar
• Pfister T, Atzpodien E, Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 2003; 191: 159–67
   PubMed Web of Science ®Google Scholar
• Cal JC, Daley-Yates PT. Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD), in rats and mice. Toxicology 1990; 65: 179–97
   PubMed Web of Science ®Google Scholar
• CEDR New and Generic Drug. Approval Zometa (zoledronic acid) injection, Part 2, NDA 21–223, Pharmacol Rev, Pharmacokinet. Summary ( http://www.fda.gov/cder/foi/nda/2001/21-223_Zormeta_pharmr_P2.pdf). 1998.
   Google Scholar
• Pfister T, Atzpodien E, Bauss F. Preclinical renal safety profile of ibandronate. Bone 2008; 42(Suppl 1)S105–S106
   Web of Science ®Google Scholar
• Polascik TJ, Given RW, Metzger C, Julian SR, Vestal JC, Karlin GS, et al. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 2005; 66: 1054–9
   PubMed Web of Science ®Google Scholar
• Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, et al. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 2007; 109: 1090–6
   PubMed Web of Science ®Google Scholar
• Lameire NH, Flombaum CD, Moreau D, Ronco C. Acute renal failure in cancer patients. Ann Med 2005; 37: 13–25
   PubMed Web of Science ®Google Scholar
• Polascik TJ, Mouraviev V. Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag 2008; 4: 261–8
   PubMedGoogle Scholar
• Carey JJ, Palomo L. Bisphosphonates and osteonecrosis of the jaw: Innocent association or significant risk?. Cleve Clin J Med 2008; 75: 871–9
   PubMed Web of Science ®Google Scholar
• Reid IR. Osteonecrosis of the jaw: Who gets it, and why?. Bone 2009; 44: 4–10
   PubMed Web of Science ®Google Scholar
• Wardley A, Body JJ, Neary MP. A time-in-motion study of oral ibandronate versus iv zoledronic acid for treatment of metastatic bone disease in breast cancer patients. J Clin Oncol 2005; 23: 16s
   Google Scholar
• Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004; 9(Suppl 4)28–37
   PubMed Web of Science ®Google Scholar